Karyopharm Therapeutics Inc. — Q1 2014 Form 10-Q
Reporting period: Three months ended March 31, 2014. Karyopharm is a clinical-stage biotechnology company developing SINE compounds targeting XPO1. Its lead candidate, selinexor (KPT-330), was being studied in Phase 1 and Phase 2 trials; the company reported that more than 300 patients had been treated. The company had no drug-sale revenue.
Financial performance and position
| Metric | Q1 2014 | Q1 2013 / comparison |
|---|---|---|
| Contract and grant revenue | $171,000 | $233,000 |
| Research and development expense | $11.0 million | $5.0 million |
| General and administrative expense | $2.9 million | $879,000 |
| Net loss | $13.7 million | $5.6 million |
| Net loss per share, basic and diluted | $0.46 | $2.52 |
| Cash used in operating activities | $10.6 million | $5.2 million |
| Cash and cash equivalents, March 31 | $144.9 million | $155.0 million at December 31, 2013 |
All financial amounts are in U.S. dollars. The company reported no meaningful operating margin: it incurred operating expenses substantially in excess of its limited grant revenue. No debt balance was reported in the balance sheet. Current liabilities were $5.0 million, against $147.6 million of current assets. Cash and cash equivalents were primarily held in money market funds. The filing does not provide a product gross margin because the company had no drug sales.
Changes versus the prior comparable period
- Net loss increased to $13.7 million from $5.6 million, while operating cash use rose to $10.6 million from $5.2 million.
- R&D expense increased by $6.0 million, reflecting higher consulting and personnel costs, clinical-trial spending, discovery work, and IND-enabling toxicology studies.
- G&A expense increased by approximately $2.0 million, primarily from higher personnel, consulting, legal and other professional fees, insurance, and state taxes.
- Revenue fell by $62,000, which management attributed to smaller grant milestones recognized in the quarter.
Liquidity, outlook, risks, and other items
- Management expected existing cash to fund its current operating plan and capital expenditure requirements into early 2016. It also expected expenses and operating losses to increase as clinical development continued and stated that substantial additional funding would be needed to achieve its objectives.
- Management identified clinical-trial progress and results, regulatory review, development costs, collaboration opportunities, and potential commercialization spending as factors affecting future funding needs. If additional financing is unavailable on acceptable terms, the company may have to delay, reduce, or eliminate programs.
- In March 2014, the company entered a lease for approximately 29,933 square feet, beginning May 2014 and ending October 2021. Aggregate rent payments were approximately $5.6 million; the contractual-obligations table reported $5.689 million in operating lease obligations. A $400,000 letter of credit was recorded as restricted cash.
- There were no material subsequent events reported through the filing date, no legal proceedings reported, and no material changes to the risk factors in the 2013 Form 10-K. Management concluded disclosure controls were effective at the reasonable-assurance level and reported no material change in internal control over financial reporting.
- The company had foreign-currency exposure from contracts with certain Canadian and European vendors and did not hedge that exposure. Management said a 10% immediate interest-rate change would not materially affect the value of its short-term investment portfolio.
Important facts for investors to verify
- Whether selinexor’s clinical progress and trial results support the anticipated registration-directed studies, and whether those studies begin as planned.
- Whether the stated cash runway into early 2016 remains achievable as R&D spending and clinical activity increase, and the timing and terms of any additional financing.
- The components and sustainability of the quarter’s expense growth, including stock-based compensation and clinical-development costs.
- The future cash and operating-cost impact of the new facility lease and related commitments.
- That the reported $0.46 Q1 2014 loss per share is not directly comparable to the $2.52 Q1 2013 figure without considering the large difference in weighted-average shares outstanding following the IPO.